BioNTech Pins Its Future on Pumitamig as ASCO Arrives With Vaccine Revenues in Retreat

BioNTech enters its most consequential week of the year as the American Society of Clinical Oncology annual meeting kicks off in Chicago, bringing late-stage cancer data that will test whether the German biotech can finally sever its dependence on COVID-19 vaccine sales. The stakes are high, and the market is watching closely: shares closed Friday at €82.35, gaining 2.68% on the day, but still trading nearly 19% below their 52-week high of €101.90.

Investors have already priced in a vaccine downturn. First-quarter revenue slid to €118.1 million ($138.0 million), down from €182.8 million a year earlier, as the company booked a net loss of €531.9 million ($622.3 million). Research spending — dominated by immuno-oncology candidates such as Pumitamig and Gotistobart — accounted for the bulk of the outflow. Against that backdrop, the European Commission’s decision on May 29 to update the pediatric COVID-19 vaccine authorization for children aged six months to four years felt more like a regulatory footnote than a catalyst. The change simplifies the regimen: instead of three 3-microgram doses, children in that age group will now receive two 10-microgram shots, aligning them with older children. The approval, covering all 27 EU member states plus Iceland, Liechtenstein and Norway, followed a positive EMA recommendation from April 23. But with vaccine revenue expected to keep shrinking in Europe and the U.S. for the full year, the real question for shareholders is whether the oncology pipeline can begin delivering commercial results.

That answer may start taking shape at ASCO, where BioNTech is presenting a concentrated batch of clinical readouts. The centerpiece is Pumitamig, its lead bispecific antibody candidate. An interim analysis from the dose-optimization portion of the phase 2/3 ROSETTA Lung-02 trial showed encouraging anti-tumor activity in first-line non-small cell lung cancer, covering both squamous and non-squamous histologies across all PD-L1 expression levels and excluding patients with targetable genomic alterations. The data feed into an ongoing pivotal phase 3 study in which Pumitamig plus chemotherapy goes head-to-head against Merck’s established first-line standard, Keytruda. It is arguably the most competitive field in oncology, and BioNTech’s performance here will shape investor confidence in its broader platform.

Should investors sell immediately? Or is it worth buying BioNTech?

Elsewhere in the pipeline, BioNTech is presenting phase 2 results for Gotistobart in heavily pretreated, platinum-resistant ovarian cancer. The CTLA-4-targeting agent aims to deplete regulatory T cells and has shown durable anti-tumor activity, clinically meaningful overall survival and a manageable safety profile. The company is also advancing antibody-drug conjugates, including Trastuzumab Pamirtecan, for which a U.S. filing is planned this year. By year-end, management expects to have 15 active phase 3 studies, with seven late-stage oncology data packages scheduled for 2026.

Financially, BioNTech is well-positioned to fund that ambition. It ended the first quarter with $19.6 billion in cash and marketable securities — roughly €16.8 billion — and has authorized a share buyback of up to $1.0 billion over the next twelve months. At the same time, it is aggressively cutting costs. A restructuring plan affecting approximately 1,860 positions across production sites in Idar-Oberstein, Marburg, Singapore and at CureVac facilities is expected to generate annual savings of around $584.9 million by 2029.

The technical picture reflects the market’s cautious optimism. Friday’s close of €82.35 put the stock just above its 50-day moving average of €81.06, but still beneath the 200-day line at €86.18. The March low of €72.50 marked a recovery floor, but sustained upside likely depends on clinical, not regulatory, catalysts.

Analysts remain broadly constructive despite the weak share price. The consensus of 17 analysts points to a target of $125.45, though the range is wide. Canaccord Genuity recently trimmed its target to $158 from $171 while keeping a positive stance, while Leerink sits at the more cautious end with $94. For now, the market is waiting to see whether the data flowing out of Chicago will narrow that gap — or widen it.

Ad

BioNTech Stock: New Analysis - 30 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH | boerse | 69449001 |